治疗性疫苗
Search documents
迈科康生物筹备A股上市:董事长陈德祥是海归博士,曾任职于辉瑞、诺华
Sou Hu Cai Jing· 2025-12-18 02:16
| 辅导对象 | 成都迈科康生物科技股份有限公司 | | | | --- | --- | --- | --- | | 成立日期 | 2016年4月29日 | | | | 注册资本 | 3.726.1289 万元 | 法定代表人 | DEXIANG CHEN ( ) 德祥) | | 注册地址 | 四川省成都高新区科园南路 88号 12 栋 6层 608号(自编号) | | | | 控股股东 及持股比 例 | 公司控股股东为成都谦鼎企业管理咨询有限公司,直接持有公司 22.09%股权 | | | | 行业分类 | C27 医药制造业 无 | 在其他交易 场所(申请) 挂牌或上市 | | | | | 的情况 | | | 注 | 无 | | | 目前,迈科康生物控股股东为成都谦鼎企业管理咨询有限公司,直接持有公司 22.09%股权。 官网显示,迈科康生物董事长,总经理为陈德祥,首席科学家为Mark R. Alderson。 陈德祥,密西西比州立大学免疫学博士,先后在辉瑞(Pfizer)、诺华(Novartis)和帕斯适宜(PATH) 科技组织从事疫苗和疫苗佐剂开发工作超30年,期间主持了多项由国际组织、基金会和国家政 ...
康泰生物:与阿斯利康签署许可终止协议
Xin Lang Cai Jing· 2025-09-30 08:05
Core Viewpoint - The company has terminated its collaboration with AstraZeneca on the development, production, and commercialization of the ChAdOx1 adenovirus vector COVID-19 vaccine due to changes in the epidemic strain and market environment, as well as resource allocation considerations [1] Group 1: Collaboration Termination - The termination of the collaboration is a cautious decision based on the evolving COVID-19 vaccine landscape and market conditions [1] - The company has signed a License Termination Agreement with AstraZeneca [1] Group 2: Future Focus - The company currently has nearly 30 projects in development, covering important categories such as multivalent vaccines and innovative vaccines [1] - Future resource allocation will concentrate on the research and industrialization of multivalent vaccines, adult vaccines, innovative vaccines, and therapeutic vaccines to enhance core competitiveness [1]
34颗未来产业“金种子”破“赛”而出
Xin Hua Ri Bao· 2025-07-28 01:40
Core Insights - The Jiangsu Future Industry Innovation and Entrepreneurship Competition showcased 56 projects focusing on key future industries such as brain-computer interfaces, new materials, hydrogen energy, and advanced storage, with 34 projects selected as "gold seeds" for investment [1][2][6] Group 1: Competition Overview - The competition is a significant platform for nurturing future industries in Jiangsu, organized by the Provincial Development and Reform Commission and supported by various investment and entrepreneurial associations [2] - The number of projects registered for this year's competition increased by nearly 40% compared to the first edition, indicating growing interest and innovation in the sector [2] - The final round involved rigorous processes including live presentations and real-time scoring, highlighting the high quality of projects that advanced to this stage [2] Group 2: Investment Opportunities - Winning projects will enter the Jiangsu Strategic Emerging Industry Fund's future industry angel fund project reserve, providing them with potential investment opportunities [3][6] - The Jiangsu Strategic Emerging Industry Fund has reached a scale of over 100 billion, establishing a solid foundation for the growth of emerging industries [2][6] - Successful cases from the fund include a 10 million yuan investment in a biotechnology company aimed at accelerating clinical research for cancer treatments [3] Group 3: Ecosystem and Support - The competition is part of a broader strategy to cultivate future industries through collaboration among government, enterprises, research institutions, finance, and society [5][6] - The Jiangsu government is implementing a three-year action plan (2024-2026) to accelerate the development of future industries, with the competition serving as a key initiative [5][6] - The selected projects will receive continuous support and tracking services from the Jiangsu High-tech Investment Group, enhancing their chances of success [6]
前瞻全球产业早报:最严电动自行车国标即将实施
Qian Zhan Wang· 2025-07-21 12:41
Group 1 - The Ministry of Industry and Information Technology aims to promote innovation in future industries such as humanoid robots, the metaverse, and brain-computer interfaces, while accelerating the development of biomanufacturing and low-altitude industries [2] - The Ministry of Commerce plans to continue reducing restrictive measures in the service consumption sector during the 14th Five-Year Plan period, focusing on enhancing service quality and expanding supply in areas like healthcare and elderly care [3] Group 2 - A new mandatory national standard for electric bicycles, GB 17761—2024, will be implemented on September 1, 2025, setting a maximum design speed of 25 km/h and requiring automatic power cut-off for speeds exceeding this limit [4] - China's L2-level assisted driving penetration rate has surpassed 50%, leading globally, with parking assistance technology also seeing over 20% penetration in mid-to-high-end models [5] Group 3 - The humanoid robot company UBTECH has unveiled a groundbreaking technology that allows its robots to autonomously change batteries without shutting down, enhancing operational efficiency and reducing maintenance costs [6] - Xiaopeng Motors' CEO predicts that low-altitude flying vehicles will transform urban transportation within the next decade, with the company already having significant experience in this field [7] Group 4 - Starbucks China has formed a strategic partnership with Envision Group to develop a digital carbon management platform, aiming to measure and reduce the carbon footprint of its supply chain over the next three years [10] - Germany's total fertility rate has dropped to 1.35 in 2024, the lowest in 17 years, indicating demographic challenges [11] Group 5 - Meta has hired two AI researchers from Apple to enhance its capabilities in artificial intelligence [12] - OpenAI has launched ChatGPT Agent, a unified intelligent agent capable of autonomous thinking and tool selection for complex tasks [13] Group 6 - Uber plans to invest hundreds of millions of dollars in partnerships with Lucid and Nuro to launch autonomous taxis in the U.S. by 2026, with a goal of deploying at least 20,000 vehicles within six years [14] - Japanese semiconductor manufacturer Rapidus maintains its goal of mass production by 2027, focusing on 2nm technology [14] Group 7 - BP has agreed to sell its U.S. onshore wind energy business to LS Power [15] - Sanofi has completed the acquisition of Blueprint Medicines for over $9 billion, including a rare disease drug that has received regulatory approval [15]